Safe Handling of Oral Anti cancer Agents: Perspectives from Breast Cancer Patients at National Cancer Centre
|
|
- Muriel Maxwell
- 6 years ago
- Views:
Transcription
1 Safe Handling of Oral Anti cancer Agents: Perspectives from Breast Cancer Patients at National Cancer Centre ABSTRACT Sim M.H. 1, Leow Y.C. 2 and Chan A. 3 Department of Pharmacy, Faculty of Science, National University of Singapore 10 Kent Ridge Road, Singapore National Cancer Centre 11 Hospital Drive, Singapore Objectives: To investigate breast cancer patients attitude, adherence and practices with their oral anti cancer agents. For the purpose of this paper, anti cancer agents would include cytotoxics and hormonal agents. Method: A single centre, cross sectional, interviewer administered survey was carried out at the Outpatient Pharmacy of National Cancer Centre (NCC), Level 1. Descriptive statistics were evaluated using Statistical Package for Social Science (SPSS) Results: Of the 126 surveys, 121 fit the inclusion criteria, of which 57 are breast patients. Only 10 (17.5%) indicated that oral and parenteral anti cancer agents are equally potent. Eight (14.0%) considered their oral anti cancer agents to be more potent than the parenteral ones. All disagreed or strongly disagreed that it was difficult to understand their regiment and 51 (89.5%) disagreed or strongly disagreed that it was difficult to adhere. 49 (86.0%) would dispose the bottles used to contain their oral anti cancer agents directly or indirectly down the chute and only six (10.6%) would inform their healthcare professionals about any leftover medications before the next refill or appointment. Conclusions: Patients seemed to be able to understand and adhere to the treatment regimen well. However, more can be done to educate patients about the nature of oral anti cancer agents and their safe handling. INTRODUCTION There is a high incidence of breast cancer in Singapore. From 2001 to 2005, breast cancer was the most frequent cancer among local females, accounting for 29.4% of all incidences (Lee, 2007). Breast cancer incident rate in Singapore has increased at an annual average rate of 3.6% from 1968 to 1992 and this rate is expected to increase more sharply in the future (Seow, 1996). Once diagnosed, modalities include surgery, as well as adjuvant drug therapy. Adjuvant therapy includes radiation therapy, chemotherapy and/or hormone therapy. Conventionally, chemotherapy is given intravenously. With the development of oral anticancer agents, patients have more choices and improved convenience with receiving treatment 1 Student 2 Student 3 Assistant Professor 1
2 than before. Yet, this implies that patients have to assume greater responsibilities for their treatment, with regards to adherence and safe handling of their medications (potential biohazards). However, many studies have shown the decrease of adherence to tamoxifen over time and rates of adherence to oral chemotherapy range from less than 20 to 100%. For example, adherence (defined as patients having their prescriptions filled and medicines available on at least 80% of the days) to tamoxifen therapy in the long term has been found to be dependent on patients perceived risks associated with the disease, benefits from therapy, nature and severity of side effects; their knowledge and understanding of their condition, financial resources as well as complexity and duration of the regimen (Viele, 2007). Another agent, anastrozole also showed that patient s adherence decreased over time and patients may be suboptimally adherent (Partridge, 2008). At the National Cancer Centre (NCC), oral cytotoxics such as Capecitabine (Xeloda ) is used for chemotherapy; Tamoxifen, Anastrozole (Arimidex ), Letrozole (Femara ) and Exemestane (Aromasin ) are commonly used for hormone therapy. With the exception of Tamoxifen, the remaining medications have been approved by FDA only in the last ten years. As such, specific guidelines to their safe handling have not yet been established. However, good practices include having patients and/or their caregivers to wash their hands before and after handling their medication even if they wear gloves and to return unused medication to the pharmacy for disposal instead of discarding them in the household trash or flushing them down the toilet to avoid contaminating landfills and water supplies. Patients and their caregivers are also advised not to crush the tablets and/or open the capsules to avoid releasing particulate matter which contaminates the environment and also potentially put others at increased risk of exposure to these anti cancer agents (Bartel, 2007). Given the relative novelty of these agents, safety studies have not been done to evaluate these chemotherapeutic drugs for mutagenic effects due to increased exposure. Therefore, it is prudent to do a study on patients practices with both cytotoxics and hormonal agents. METHOD The study was a single centre, cross sectional, interviewer administered survey. Cancer patients seen at the Outpatient Pharmacy of NCC, who are currently treated on oral anti cancer treatment, either as chemotherapy or hormone therapy are interviewed. Patients recruited must have either been on the medicine for at least a cycle (chemotherapy) or three months (hormone therapy) if the medicine is their first oral anti cancer medicine and/or have been on other forms of oral anti cancer medicines. Before the survey, all patients (or caregivers) are required to give their consent and are informed of their rights and that participation is strictly voluntary. In further compliance with ethical requirements, the survey was subjected to approval by the Institutional Review Board (IRB) and both interviewers underwent an online training on the modules Human Research and Good Clinical Practice with Collaborative Institutional Training Initiative (CITI). To ensure that patients (or caregivers) fully understood the questions, only patients who are able to speak English or Mandarin are interviewed. In addition, as the data are collected by two interviewers, a Mandarin version of the survey questions was available to ensure that the meaning conveyed to the patients was as close as possible to the intended meaning and there is maximal consistency among the interviewers. 2
3 All data were validated before use. Surveys with more than two questions incomplete and patients who do not seem to be able to understand the questions asked of them are omitted. The remaining data are then analysed using Statistical Package for Social Sciences (SPSS). Descriptive statistics are obtained to identify patients practices with their medicines, attitude and adherence to their regimen. RESULTS A total of 126 surveys were collected. Five were rejected as they do not meet the inclusion criteria. Of the remaining surveys, 57 (47.2%) involved breast cancer patients; of which 27 (47.4%) were on tamoxifen, 11 (19.3%) on anastrozole, eight (14.0%) on letrozole, eight (14.0%) on capecitabine and three (5.3%) on exemastane. Patients demographics All patients interviewed with breast cancer were females. Figure 1: Histogram and normal curve of age distribution of patients Age Frequency Age Mean =54.91 Std. Dev. = N =57 The mean age of the patients was about 55 years, with the majority of the patients falling in the range of 50 to 65 years old. 3
4 Table 1: Educational level of patients Educational level Frequency Percent (%) Uneducated Primary Secondary Pre University University Unknown More than half (54.4%) had secondary school education with the majority (79.0%) having only secondary school education or less. Two (3.5%) of the patients educational level was unknown because the survey was conducted with the caregivers who were not aware of their educational levels. Figure 2: Bar graph showing distribution of cancer stages of patients Cancer_stage Frequency I II III IV 0 Cancer_stage Majority of the patients (68.4%) had early stage breast cancer stage 0 to II. The remaining 18 (31.6%) had late stage breast cancer. Stage 0 breast cancer refers to patients with carcinoma in situ. In addition, 56 (98.2%) of the patients had ECOG staging of 1 and only one (1.8%) with ECOG staging of 2. 4
5 Table 2: Number of comorbidites of patients Number of comorbidites Frequency Percent (%) The comorbidites that were taken into consideration includes hypertension, diabetes, hypercholesterolemia, asthma, hyperthyroidism and heart enlargement. The majority of the patients (82.5%) had none or one comorbidites. A minority (17.5%) had two or more comorbidites. Patients attitude towards oral anti cancer agents Patients were asked to compare the safety and potency of oral and parenteral anti cancer agents. Only seven (12.3%) felt that oral and parenteral anti cancer agents are equally toxic. About half (43.9%) felt that oral anti cancer agents are safer than the parenteral ones and another 23 (40.4%) responded that they do not know if oral anti cancer agents are safer than parenteral treatment. One (1.8%) felt that none is safe and one (1.8%) felt that oral anti cancer agents are not safer than the parenteral treatment. More than half (52.6%) responded that they do not know if oral anti cancer drugs are as potent as parenteral anti cancer drugs. Only 10 (17.5%) felt that they have the same potency. On the other hand, eight (14.0%) actually considered the oral ones to be more potent than the parenteral treatment. Nine (15.8%) indicated that the oral ones are not as potent as the parenteral ones. Dosing and Compliance All patients administered their own oral anti cancer agent, except for one; where the maid was the caregiver administering the agent. 51 (89.5%) disagreed or strongly disagreed that it was difficult to adhere to their regimen. Only two (3.5%) were neutral and four (7.0%) agreed that it was difficult to adhere to their regimen. When asked to rate their adherence (with 10 being very adherent and 1 as not adherent), the mean score was 9.42, with the median and mode as 10. All disagreed or strongly disagreed that it is difficult to understand their dosing schedule. All but two claimed that they would not change the dosage on their own. Of the two who would change the dosage, one would decrease the dose and one would skip a dose. The reason they changed the dose was due to side effects. However, when asked what they would do if they missed a dose of their oral anti cancer medicine, a variety of responses were given. None of the patients on capecitabine replied that they would resume taking the dose if it is within six hours of the missed dose and only seven (14.3%) of the patients on hormonal agents replied that they would resume taking dose if it is within twelve hours of the missed dose. 5
6 Table 3. Responses of patients on capecitabine to a missed dose, n=8 Responses Frequency Percent (%) Skip the dose Resume taking the dose when remember Skip the dose if more than 3 hours Resume if within 12 hours Table 4. Responses of patients on hormonal agents to a missed dose, n=49 Responses Frequency Percent (%) Skip the dose Resume taking the dose if within 6 hours Resume taking the dose within 12 hours Resume taking the dose when remember Resume taking when remember; skip if too close to next dose I do not know The majority (94.7%) felt that follow up appointments and laboratory tests are important and should not be missed. Storage and handling More than half (52.6%) claimed that they would store their oral anti cancer agents separately from other medications. All patients interviewed also indicated that they would not wear gloves when handling their oral anti cancer agents; though one claimed that her caregiver wears gloves. More than half (52.6%) responded that they do not wash their hands after handling their oral chemotherapeutics. Only 15 (26.3%) would wash their hands though one claimed that she would wipe her hands with alcohol disinfectant instead of washing. Nine (15.8%) were not consistent in washing their hands and two (3.5%) could not remember if they washed their hands after handling their oral chemotherapeutics. All claimed that they would not crush their tablets or open the capsules. Table 5.1. How patients would handle their dropped medication, n=57 Frequency Percent (%) Depends on location Independent of location Never dropped before
7 Table 5.2. Course of action taken by patients after picking up the dropped medication, n=57 Frequency Percent (%) Consume Throw Never dropped before Only 15 (26.3%) would throw their dropped medication into the bin regardless of location. More than half (64.9%) would pick up their medication with their fingers or receptacles and consume; though five (8.8%) insisted that they have never dropped their medication before and would therefore not want to consider the hypothetical situation. Of the 27 (47.4%) patients who were asked how they would pick up the dropped medication before throwing or consuming it, 25 (92.6%) would pick up the medication with their fingers and only two (7.4%) would pick up using receptacles. None of the patients would bring the bottles of their oral anti cancer agents to the pharmacy for disposal. Two thirds (66.7%) would throw them into their home waste paper basket which is emptied daily and 11 (19.3%) would throw them directly into the chute. Generally, these bottles were disposed similarly to their household trash. Two (3.5%) claimed that they would keep the bottles for reference and two (3.5%) would throw them into recycling bags. When asked what they would do with leftover medication before the next appointment or refill, more than half (54.4%) would continue with their medication and one patient who is on capecitabine claimed that he would continue into the rest period of the cycle. Only six (10.6%) indicated that they would tell or show the extra medication to their doctors or pharmacists. 10 (17.5%) of the patients responded that they never had extras before and hence would not consider the hypothetical situation. DISCUSSION Patients generally seemed to have no problems with understanding and adhering to their anticancer treatment regimen. However, their varied responses to a missed dose suggest that patients are probably too complacent with their medication habits. It was also surprising that 14.0% considered their oral anti cancer agents to be more potent than the parenteral ones. Patients ignorance about the nature of oral anti cancer agents is further highlighted when 43.9% felt that the oral anti cancer agents are safer than parenteral anti cancer agents. This underestimation of their oral anti cancer agents might account for patients complacency. Patients handling practices with their oral anti cancer agents also showed their lack of knowledge in this area as well as lack of understanding about the nature of the medicine. The oral anti cancer agents were regarded by patients as any other ordinary medicine as shown when more than half (64.9%) would pick up and consume their dropped medications. When disposing dropped medication or empty bottles of their oral anti cancer agents, these were regarded as ordinary household trash, with 86% disposed directly or indirectly down the chute. Similarly, when there were leftover medications, only 10.6% would highlight this to their healthcare professionals. This is again probably due to patients lack of knowledge or complacency with their medication. 7
8 Limitations As patients were required to recall their practices and adherence to their medication, recall bias was an inherent limitation of this study. Patients were also assumed to be entirely honest with the interviewers, especially when asked about their adherence to the treatment regimen. Furthermore, as only Mandarin and/or English speaking patients were included in this study, there could be a slight bias against patients from other races who were not able to speak the above two languages. CONCLUSION Patients clearly need to be educated about the nature of their medications, particularly on how they should handle and dispose of their medication appropriately. Though all patients are educated on how to take their oral anti cancer agents and the course of action in the event of a missed dose, more can definitely be done to reinforce their knowledge. The current practice of giving patients an information leaflet about their medication does not seem to be effective. Healthcare professionals could also play a more active role in educating their patients to allow patients to assume appropriate responsibility in managing their condition and medication. In addition, as these patients do not bring to the attention of their healthcare providers in the event of leftover medications, all healthcare providers should be more proactive in checking any such balances with patients. REFERENCES Partridge, A. H., LaFountain, A., Mayer, E., Taylor, B. S., Winer, E., Asnis Alibozek, A.(2007), Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early Stage Breast Cancer, Journal of Clinical Oncology, Vol 26(4), pp Bartel S.B. (2007), Safe practices and financial considerations in using oral chemotherapeutic agents, Am J Health Syst Pharm, Vol 64, Suppl 5, S8 S11 Lee, H.P., Ling, A., Chow, K.Y. and Razal, L.A. (2007), Singapore Cancer Registry Interim Report Trends in Cancer Incidence in Singapore , National Registry of Diseases Office Seow, A., Duffy, S.W., McGee, M.A., Lee, J. and Lee, H.P. (1996), Breast Cancer in Singapore: Trends in Incidence , International Journal of Epidemiology, Vol 25(1), pp Viele, S.C. (2007), Managing oral chemotherapy: The healthcare practitioner s role, Am J Health Syst Pharm, Vol 64, Suppl 5, S26 ACKNOWLEDGEMENTS The author would like to thank Dr. Alexandre Chan for his kind guidance and the pharmacists at the National Cancer Centre for their assistance. 8
ORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name letrozole (LEH-truh-zole) Brand name Femara (FEH-muh-ruh) Approved uses Letrozole is used in the treatment of certain types of hormone-dependent breast cancer in postmenopausal
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name tamoxifen citrate (tuh-mok-sih-fen SIH-trayt) Brand name Soltamox (SOL-ta-mox) Approved uses Tamoxifen is used to treat certain types of hormone-dependent breast cancer
More informationSorafenib (Nexavar ) ( sor-af-e-nib )
Sorafenib (Nexavar ) ( sor-af-e-nib ) How the drug is given: by mouth Purpose: To stop the growth of cancer cells in kidney cancer, liver cancer, and other cancers How to take the drug by mouth Take on
More informationEverolimus (Afinitor )
Everolimus (Afinitor ) ( e-ver-oh-li-mus ) How drug is given: By mouth Purpose: to slow the growth of cancer cells in kidney cancer and other cancers How to take the drug Take with or without food and
More informationEltrombopag (Promacta )
Eltrombopag (Promacta ) ( el TROM boe pag ) How drug is given: By mouth Purpose: to treat aplastic anemia and increase low platelet counts in some conditions How to take this drug 1. Take this medication
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name Ruxolitinib (RUK-soh-LI-ti-nib) Brand name Jakafi (JA-kah-fy) Approved uses Ruxolitinib is used to treat patients with myelofibrosis and polycythemia vera. Dose and
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name thioguanine (THY-oh-GWAH-neen) Brand name Tabloid (TAB-loyd) Approved uses Thioguanine is used to treat adult and pediatric patients with acute myeloid leukemia (AML).
More informationImatinib (Gleevec ) ( eye-mat-eh-nib )
Imatinib (Gleevec ) ( eye-mat-eh-nib ) How drug is given: by mouth Purpose: stops growth of cancer cells in leukemia, gastrointestinal stromal tumors (GIST), and other cancers How to take the drug by mouth
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name abiraterone acetate (A-bih-RA-the-rone A-seh-tayt) Brand name Zytiga (zye-tee-ga) Approved uses Abiraterone acetate is used in combination with prednisone to treat
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name vismodegib (VIS-moh-DEH-gib) Brand name Erivedge (AYR-ih-vej) Approved uses Vismodegib is used to treat advanced or metastatic basal cell carcinoma. Dose and schedule
More informationIbrutinib (Imbruvica )
Ibrutinib (Imbruvica ) ( eye BROO ti nib ) How drug is given: by mouth Purpose: to stop the growth of cancer cells in lymphoma and other cancers How to take the drug Take each dose at the same time every
More informationDabrafenib (Tafinlar )
Dabrafenib (Tafinlar ) ( da-braf-e-nib ) How drug is given: By mouth Purpose: To stop the growth of cancer cells in melanoma and other cancers. How to take this drug Take this medication on an empty stomach
More informationMidostaurin (Rydapt )
Midostaurin (Rydapt ) ( mye doe STAW rin ) How drug is given: By mouth Purpose: To stop the growth of cancer cells in acute myeloid leukemia (AML) and other cancers. How to take this drug 1. Take this
More informationLenvatinib (Lenvima ) ( len-va-ti-nib )
Lenvatinib (Lenvima ) ( len-va-ti-nib ) How drug is given: By mouth Purpose: To treat thyroid cancer or other cancers How to take this drug This medicine can be taken with or without food. Take each dose
More informationNorth of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines
\ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name procarbazine (proh-kar-buh-zeen) Brand name Matulane (MA-choo-layn) Approved uses Procarbazine is used to treat Hodgkin s disease. Dose and schedule Taking procarbazine
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name etoposide (ee-toh-poh-side) Brand name VePesid (ve-pe-sid) Approved uses Etoposide is used to treat adults with small cell lung cancer and testicular cancer. Dose and
More informationSafe handling of oral anticancer agents
What do we mean by safe handling? Safe handling of oral anticancer agents Jude Lees Senior Pharmacist Royal Adelaide Hospital Cancer Centre Adelaide, South Australia Exposure with IV chemo Many Oral Agents
More informationREFERENCE NUMBER: NH.PST.05 EFFECTIVE DATE: 10/10
PAGE: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationSAFE Needle Disposal
SAFE Needle Disposal What s in this toolkit? A. Reasons for using needles B. Needle use in pictures C. Who can get poked accidentally? D. What are the risks of touching used needles? E. Unsafe ways to
More informationOral Systemic Therapy
Patient & Family Guide 2018 Oral Systemic Therapy www.nscancercare.ca Patient s Name: Type of Treatment: Cancer Doctor: Cancer Clinic: Phone Number: Emergency Department Phone Number: Who do I call if
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOral Systemic Therapy
Oral Systemic Therapy This information does not take the place of the care and advice of your Cancer Care Team. Talk to your Cancer Care Team about your health concerns, treatment options and any questions
More informationCHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY
CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY Version 4.0 March 2016 Review date March 2018 Introduction It is the purpose of this policy to provide clear guidelines that
More informationStarting with Tivicay
Starting with Tivicay (dolutegravir) Read the package leaflet thoroughly before you use Tivicay. PATIENT INFORMATION Introduction You have been given this brochure because you will be using Tivicay and
More informationFAQs on Proper Disposal of Drugs
FAQs on Proper Disposal of Drugs In the past, you might have been told it was best to discard medications by flushing them. What has changed? There is a new awareness about the potential harmful effects
More informationPractice Advisory on Drug Coverage Parity across Medical and Pharmacy Benefits
Practice Advisory on Drug Coverage Parity across Medical and Pharmacy Benefits Introduction Oncology medications have historically been administered intravenously in a physician s office, infusion center
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name ixazomib (ik-sa-zoh-mib) Brand name Ninlaro (nin-lar-oh) Approved uses Ixazomib is used to treat multiple myeloma (MM) in combination with lenalidomide and dexamethasone.
More informationOLDER ADULT TOOLKIT Trivia Game Facilitator s Guide
SLIDE 1 Note to facilitator: Before starting the game, complete these tasks: 1. Split the participants into teams of 4-6 people. Ask each team to create a team name. 2. Collect the team names and create
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name niraparib (nih-ra-puh-rib) Brand name Zejula (zeh-joo-luh) Approved uses Niraparib is used to treat adult patients with recurrent fallopian tube cancer, ovarian cancer,
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name lapatinib (luh-pa-tih-nib) Brand name Tykerb (TY-kerb) Approved uses Lapatinib is used in combination to treat advanced or metastatic breast cancer that overexpresses
More informationSafe Medication Use. Patient Teaching Slides
Safe Medication Use Patient Teaching Slides 3 Ways to Improve Medication Safety 1. Talk to your Doctor or Pharmacist about Your Medications 2. Organize, Store, Secure, and Dispose of Your Medications Safely
More informationINSTRUCTIONS FOR USE TYMLOS (tim lows ) (abaloparatide) injection, for subcutaneous use
INSTRUCTIONS FOR USE TYMLOS (tim lows ) (abaloparatide) injection, for subcutaneous use Instructions for Use Read and follow this Instructions for Use so that you inject TYMLOS pen the right way. Call
More informationStandard Operating Procedure for Use of Opioid Transdermal Patches in homes within NHS Sutton CCG
Standard Operating Procedure for Use of Opioid Transdermal Patches in homes within NHS Sutton CCG Introduction This procedure is intended to encourage good practice in the management of opioid transdermal
More informationINSTRUCTIONS FOR USE. INBRIJA (in-brih-jah) (levodopa inhalation powder) For Oral Inhalation Only
INSTRUCTIONS FOR USE INBRIJA (in-brih-jah) (levodopa inhalation powder) For Oral Inhalation Only Read and follow these instructions before you start using INBRIJA and each time you get a refill. There
More informationOral Chemotherapy Nathan Brashear, PharmD Candidate 2017 University of Kentucky College of Pharmacy
Oral Chemotherapy Nathan Brashear, PharmD Candidate 2017 University of Kentucky College of Pharmacy 1 Objectives Identify the more commonly dispensed oral chemotherapy drugs and their indications/dosage
More informationPATIENT INFORMATION What is VITRAKVI? and and
PATIENT INFORMATION VITRAKVI (vi trak vee) (larotrectinib) capsules and oral solution What is VITRAKVI? VITRAKVI is a prescription medicine that is used to treat adults and children with solid tumors (cancer)
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name brigatinib (brih-ga-tih-nib) Brand name Alunbrig (uh-lun-brig) Approved uses Brigatinib is used to treat metastatic non-small cell lung cancer (NSCLC) that has a genetic
More informationOptimal nutrition in critically ill children
Optimal nutrition in critically ill children MODULE 4 Good safety practices required for nutritional therapy Developed by The Asia Pacific Middle East Consensus Working Group on Nutrition Therapy in the
More informationLesson 5: Recording and Storage of Medication
Lesson 5: Recording and Storage of Medication Transcript Title Slide (no narration) Narrator Slide Hello. My name is Jill Morrow and I am the Medical Director for the Office of Developmental Programs.
More informationForm Breast Health Supplement to the Medication Inventory (WHI Extension Study)
154 - Breast Health Supplement to the Medication Inventory (WHI ID WHI Participant Common ID Col#1 F154DAYS Days since randomization or enrollment Col#2 Days since randomization or enrollment to receipt
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication TER Generic name venetoclax (veh-neh-toh-klax) Brand name Venclexta (ven-klek-stuh) Approved uses Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic lymphoma.
More informationINSTRUCTIONS FOR USE HUMIRA 40 MG/0.8 ML, 20 MG/0.4 ML AND 10 MG/0.2 ML SINGLE-USE PREFILLED SYRINGE
INSTRUCTIONS FOR USE HUMIRA (Hu-MARE-ah) (adalimumab) 40 MG/0.8 ML, 20 MG/0.4 ML AND 10 MG/0.2 ML SINGLE-USE PREFILLED SYRINGE Do not try to inject HUMIRA yourself until you have been shown the right way
More informationPatient Practices and Beliefs Concerning Disposal of Medications
Patient Practices and Beliefs Concerning Disposal of Medications Dean A. Seehusen and John Edwards Background: Clear guidance for how patients should dispose of unused and expired medications is lacking.
More informationSafe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009
Safe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009 Background and Situation Analysis: Consumers are rightly confused about what to do with their unwanted
More informationJylamvo 2 mg/ml oral solution (Methotrexate) Guide for Healthcare Professionals. Information to minimise the risk of medication error
2 mg/ml oral solution (Methotrexate) Guide for Healthcare Professionals Information to minimise the risk of medication error NOTE: Special warnings and precautions for use - This oral solution contains
More informationFrom the Clinic to Home: The Shift to Oral Oncolytic Therapy
From the Clinic to Home: The Shift to Oral Oncolytic Therapy Eric Vachon, BSN, RN Michigan State University, College of Nursing Disclosure I do not have anything to disclose. Objectives Oral oncolytics
More informationIMPORTANT: PLEASE READ. Don t
PATIENT/CAREGIVER INSTRUCTIONS FOR USE - ORENCIA (ABATACEPT) PREFILLED SYRINGE WITH BD ULTRASAFE PASSIVE TM NEEDLE GUARD WITH FLANGE EXTENDERS Getting started with ORENCIA therapy Did you receive self-injection
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc deliberated upon the cost-effectiveness of lapatinib plus letrozole and discussed the challenges of using letrozole alone as a comparator and/or using trastuzumab plus anastrozole as a comparator.
More informationMinnesota Plan Revision Date: July 1, Plan for Supporting Safe Collection and Proper Disposal of Home Generated Sharps
Plan for Supporting Safe Collection and Proper Disposal of Home Generated Sharps GSK Self Injectable Products Subject to these Regulations GSK currently markets, distributes, and/or sells two self-injectable
More informationMOATT Card-Style Version: A single page MOATT (PDF) is also available at the MASCC website.
MOATT V1.2 9/9/16 MOATT MASCC Teaching Tool for Patients Receiving Oral Agents for Cancer This teaching tool has been prepared to assist healthcare providers in the assessment and education of patients
More informationOral Therapies: Strategies to Ensure Adherence Jan Tipton, MSN, RN, AOCN University of Toledo Medical Center
Oral Therapies: Strategies to Ensure Adherence Jan Tipton, MSN, RN, AOCN University of Toledo Medical Center Learning Objectives Review strategies, tools, and resources to facilitate adherence among patients
More informationA Step Forward in Cancer Patient Care:
Hong Kong Pharmacy Conference 2018 A Step Forward in Cancer Patient Care: The Experience of Oncology Pharmacist-Managed Trastuzumab Clinic in Queen Mary Hospital Amy Yuen Clinical Pharmacist 24 Oct 2017.
More informationThe Self-Medication Assessment Tool (SMAT) Training Program
The Self-Medication Assessment Tool (SMAT) Training Program What is the Self-Medication Assessment Tool? The Self-Medication Assessment Tool (SMAT) is a comprehensive instrument intended to screen for
More informationPatient Information Entecavir Tablets (en-tek-ah-veer)
Patient Information Entecavir Tablets (en-tek-ah-veer) Read this Patient Information before you start taking entecavir tablets and each time you get a refill. There may be new information. This information
More informationMarch 21, Subject: Availability of Blister-Packaged XELODA (capecitabine) Tablets
March 21, 2011 Subject: Availability of Blister-Packaged XELODA (capecitabine) Tablets Dear Healthcare Professional: The purpose of this letter is to inform you of the temporary availability of an alternative
More informationGlatopa is prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis (MS).
PATIENT INFORMATION Glatopa (gluh-toh-puh) (Glatiramer Acetate Injection) for Subcutaneous Use Read this Patient Information before you start using Glatopa and each time you get a refill. There may be
More informationMedication Use safety Training FOR SENIORS
www.mustforseniors.org Medication Use safety Training FOR SENIORS Medication Use Safety Training for Seniors A National Education Campaign for Older Adults and Caregivers developed by the National Council
More informationWARNINGS AND PRECAUTIONS
DOSING GUIDE INDICATION NINLARO (ixazomib) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name palbociclib (PAL-boh-SY-klib) Brand name Ibrance (I-brans) Approved uses Palbociclib is used to treat hormone receptor positive (HR+), human epidermal growth factor
More informationUnused Medications Disposal Practice: The case of Patients Visiting University of Gondar Specialized Teaching Hospital, Gondar, Ethiopia
Unused Medications Disposal Practice: The case of Patients Visiting University of Gondar Specialized Teaching Hospital, Gondar, Ethiopia Tadele Atinafu* 1, Abayneh Takele 1, Adeladlew Kassie 1, Adane Yehualaw
More informationPharmaceuticals Returned to the PH:ARM Medicine Return Pilot in Washington
Pharmaceuticals Returned to the PH:ARM Medicine Return Pilot in Washington Study Results for a Sustainable Future Alice Chapman, P.E. Local HW Management Program in King County October 20, 2009 Outline
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name dabrafenib (duh-bra-feh-nib) Brand name Tafinlar (TA-fin-lar) Approved uses Dabrafenib is used to treat patients with: o Melanoma that has a genetic mutation called
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name acalabrutinib (uh-ka-luh-broo-tih-nib) Brand name Calquence (KAL-kwents) Approved uses Acalabrutinib is used to treat patients with mantle cell lymphoma. Dose and schedule
More informationUpdate from the 29th Annual San Antonio Breast Cancer Symposium
Update from the 29th Annual San Antonio Breast Cancer Symposium The San Antonio Breast Cancer Symposium is one of the most important breast cancer conferences. Approximately 8,000 physicians, oncologists,
More informationImproving Patient Safety and Compliance
Improving Patient Safety and Compliance Module 4 Includes Recommended Procedures Table of Contents Section A... 1 A.1 Intrathecal (IT) Doses... 1 Section B... 1 B.1 Vinca Alkaloids... 1 Section C... 2
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name temozolomide (teh-moh-zoh-loh-mide) Brand name Temodar (TEH-moh-dar) Approved uses Temozolomide is used to treat anaplastic astrocytoma and glioblastoma multiforme.
More informationEHS Guide: Laboratory Trash Removal
EHS Guide: Laboratory Trash Removal In order to minimize risk, provide safety and assure compliance with applicable federal and state regulations, any waste (trash) generated by laboratories must be properly
More informationPATIENT INFORMATION LEAFLET
Page 1 PATIENT INFORMATION LEAFLET Please read this leaflet carefully before using COMBIGAN. Keep this leaflet. You may need to read it again. If you have any further questions, please ask your doctor
More informationPRONUNCIATION: (met-for-min) COMMON BRAND NAME(S): Riomet
PRONUNCIATION: (met-for-min) COMMON BRAND NAME(S): Riomet HOW TO USE: Read the Patient Information Leaflet if available from your pharmacist before you start taking metformin and each time you get a refill.
More informationA guide to proper disposal of prescription and over-the-counter medicines.
A guide to proper disposal of prescription and over-the-counter medicines. Safe Disposal for Safer Homes The SafeMeds Program, formally West Michigan Take Back Meds Program, is a joint effort between local
More information1. Identify how oral chemotherapy marks a fundamental. 2. Are cancer patients adherent to oral therapy? A review of
2. Are cancer patients adherent to oral therapy? A review of the published literature 3. Review the factors that influence patient adherence to oral chemotherapy 4. Discuss the challenges with respect
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. XIIDRA TM* Lifitegrast Ophthalmic Solution 5%
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION XIIDRA TM* Lifitegrast Ophthalmic Solution 5% Read this carefully before you start taking XIIDRA and each time you get
More informationHand Washing Policy Policy & Procedures Manual March 2018
Hand Washing Policy Having and encouraging good hygiene practices in early childhood is essential for reducing the risk of cross infection. Helping children to develop appropriate personal hygiene habits
More informationGuidance for Pharmacists on Safe Supply of Oral Methotrexate
Guidance for Pharmacists on Safe Supply of Oral Methotrexate Pharmaceutical Society of Ireland Version 2 January 2015 Contents 1. Introduction 2 2. Methotrexate 2 3. Guidance 2 3.1 Patient Review 2 3.2
More informationDisposal by Flushing of Certain Unused Medicines: What
Disposal by Flushing of Certain Unused Medicines: What You Should Know Drugs Page 1 of 5 Disposal by Flushing of Certain Unused Medicines: What You Should Know Overview Frequently Asked Questions List
More informationPharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension)
Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension) Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management
More informationMETHOTREXATE CLINICAL PRACTICE GUIDELINES FOR STAFF
Mary Pack Arthritis Program METHOTREXATE CLINICAL PRACTICE GUIDELINES FOR STAFF Handling of premixed injectable Methotrexate (MTX) by employees who are pregnant, breast-feeding or attempting to reproduce
More informationInstructions For Use PRALUENT (PRAHL-u-ent) (alirocumab) Injection, for Subcutaneous Injection Single-Dose Pre-Filled Syringe (75 mg/ml)
Instructions For Use PRALUENT (PRAHL-u-ent) (alirocumab) Injection, for Subcutaneous Injection Single-Dose Pre-Filled Syringe (75 mg/ml) Important Information The device is a single-dose pre-filled syringe.
More informationDisposal of Unused Medicines: What You Should Know
1 of 8 3/12/16 11:14 PM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page Overview List of Medicines Recommended
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationAdherence Concepts for the Cancer Patient. Benyam Muluneh, PharmD, BCOP, CPP
Adherence Concepts for the Cancer Patient Benyam Muluneh, PharmD, BCOP, CPP Objectives Discuss the shift from intravenous to oral chemotherapy over the past few decades Assess the various dimensions of
More informationPART I. RADIONUCLIDE THERAPY WITH I-131 SODIUM IODIDE: PATIENT & DOSE ADMINISTRATOR PRECAUTIONS; ADMINISTRATION METHODS
OVERVIEW AND TOPICS Patient and dose administrator precautions and dose administration methods of therapeutic procedures Administration methods for performing therapy with I-131 sodium iodide in either
More informationMOST Operations Manual page 1 MEDICATION INVENTORY
MOST Operations Manual page 1 TABLE OF CONTENTS MEDICATION INVENTORY 1. Background and rationale... 2 2. Equipment and supplies... 2 3. Detailed measurement procedures... 2 3.1 Drug definition guidelines...
More informationMethotrexate Injections
UW MEDICINE PATIENT EDUCATION Methotrexate Injections Steps to follow Your provider has prescribed that you receive methotrexate by injection. This handout explains the drug, its side effects, drug interactions,
More informationPackage leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin
Package leaflet: Information for the patient NEGABAN 1g, powder for solution for injection or infusion Temocillin Read all of this leaflet carefully before you start using this medicine because it contains
More informationZANOSAR 1g. STREPTOZOCINE Lyophilised powder for solution for injection
PACKAGE LEAFLET: INFORMATION FOR THE USER ZANOSAR 1g STREPTOZOCINE Lyophilised powder for solution for injection Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More informationNorthumbria Healthcare NHS Foundation Trust. Your Guide to Endocrine Therapy. Issued by the Breast Team
Northumbria Healthcare NHS Foundation Trust Your Guide to Endocrine Therapy Issued by the Breast Team This leaflet is to explain about your endocrine therapy. Your guide to endocrine therapy There are
More informationCopyright 2018 DisposeRx, Inc. All rights reserved.
30 seconds breaks the chain of abuse and pollution!!! The problem starts at home; the solution: DisposeRx has developed a simple to use, inhome disposal solution for unused, unwanted, expired and/or off-therapy
More informationGSK Medicine: Study No.: Title: Rationale: before initiation of treatment, every 4-6 weeks during treatment
GSK Medicine: Lapatinib Study No.: WWE115270/WEUKSTV4275 Title: Assessment of Physician Compliance to Recommend Liver Function Test (LFT) Monitoring for Lapatinib Patients Rationale: Lapatinib (Tykerb
More informationBefore you use the TALTZ autoinjector, read and carefully follow all the step-by-step instructions.
1 INSTRUCTIONS FOR USE TALTZ (tȯl(t)s) (ixekizumab) injection, for subcutaneous use Autoinjector Before you use the TALTZ autoinjector, read and carefully follow all the step-by-step instructions. Important
More informationMedication Disposal: Questions and Answers
of 7 3/2/6 :6 PM U.S. Food and Drug Administration Protecting and Promoting Your Health Medication Disposal: Questions and Answers For safety reasons, FDA recommends that a few, select medicines be disposed
More informationEffectively managing patients receiving oral anticancer therapies to treat MBC: from a BCN perspective. Gillian Kruss
Effectively managing patients receiving oral anticancer therapies to treat MBC: from a BCN perspective Gillian Kruss New drug developments / new challenges More effective treatments (prolong O.S / PFS)
More informationOPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI)
OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI) Case 1- Prep Materials University of Massachusetts Medical School Opioid Conscious Curriculum March 2018 Learner Prep Objectives The purpose of this prep
More informationOral anticancer agent medication adherence by outpatients
2318 Oral anticancer agent medication adherence by outpatients MICHIO KIMURA 1, EISEKI USAMI 1, MINA IWAI 1, TOSHIYA NAKAO 1, TOMOAKI YOSHIMURA 1, HIROMI MORI 1, TADASHI SUGIYAMA 2 and HITOMI TERAMACHI
More informationIt does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.
Brolene Eye Drops (BRO-leen) propamidine isethionate Consumer Medicine Information (CMI) What is in this leaflet This leaflet answers some common questions about Brolene. It does not contain all the available
More informationCaring for your indwelling urinary catheter
Caring for your indwelling urinary catheter Information for patients This information is produced by the Continence, Urology and Colorectal Service Leeds Community Healthcare NHS Trust Having a urinary
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationDisposal of Unused Medicines: What You Should Know
1 of 8 04/27/2016 1:37 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page (http://www.fda.gov/aboutfda/aboutthiswebsite
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name olaparib (oh-la-puh-rib) Brand name Lynparza (lin-par-zuh) Approved uses Olaparib is used to treat ovarian, fallopian tube, or primary peritoneal cancer. Dose and schedule
More information